Soon after the World Health Organization bestowed its approval on the protein 14-3-3 as an important diagnostic marker for sporadic Creutzfeldt-Jakob disease (sCJD), reports began to come in that its sensitivity and specificity might not be all that was advertised...
As the pipeline fills with potential therapies for Alzheimer (AD) and other neurodegenerative diseases, the research community is paying increased attention to...
Calculating the risk of impending AD based on levels of CSF Aβ42 has been tricky because the peptide forms insoluble aggregates that muddle estimates of its production rate in the CNS...
Though ApoE4 genotype has for years topped the list of genetic risk factors for AD, scientists grapple with how this allele makes people more prone to AD...
In the biomarker field, potential new indicators of disease risk and prognosis leap onto the scene, yet vanishingly few finish the journey to routine clinical use...
Having established the first 42 amino acids in Aβ as a valid biomarker for AD, researchers are now turning their attention to all the other fragments of APP in the CSF...
ALS has joined the growing list of neurodegenerative diseases characterized by fluctuations in the amino acid N-acetylaspartate (NAA)—but with a twist...
Continued setbacks in Alzheimer’s disease clinical trials have fueled a sense that candidate drugs have been tested in patients whose disease has already progressed too far...
Researchers nabbed rare variants in Alzheimer’s genes by sequencing DNA from people with very high or very low levels of cerebrospinal fluid biomarkers.